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NASA has focused its future on exploration class missions including the goal of returning to the moon and landing 
on Mars.  With these objectives, humans will experience an extended exposure to the harsh environment of 
microgravity and the associated negative effects on all the physiological systems of the body.  Exposure to 
microgavity affects human physiology and results in changes to the urinary chemical composition during and after 
space flight. These changes are associated with an increased risk of renal stone formation. The development of a 
renal stone would have health consequences for the crewmember and negatively impact the success of the mission.  
As of January 2007, 15 known symptomatic medical events consistent with urinary calculi have been experienced 
by 13 U.S. astronauts and Russian cosmonauts.  
 
Previous results from both MIR and Shuttle missions have demonstrated an increased risk for renal stone formation.  
These data have shown decreased urine volume, urinary pH and citrate levels and increased urinary calcium.  
Citrate, an important urinary inhibitor of calcium-containing renal stones binds with calcium in the urine, thereby 
reducing the amount of calcium available to form calcium oxalate stones. Urinary citrate also prevents calcium 
oxalate crystals from aggregating into larger crystals and into renal stones. In addition, citrate makes the urine less 
acidic which inhibits the development of uric acid stones. Potassium citrate supplementation has been successfully 
used to treat patients who have formed renal stones.  The evaluation of potassium citrate as a countermeasure has 
been performed during the ISS Expeditions 3-6, 8, 11-13 and is currently in progress during the ISS Expedition 14 
mission. 
 
Together with the assessment of stone risk and the evaluation of a countermeasure, this investigation provides an 
educational opportunity to all crewmembers.  Individual urinary biochemical profiles are generated and the risk of 
stone formation is estimated.  Increasing fluid intake is recommended to all crewmembers.  These results can be 
used to lower the risk for stone formation through lifestyle, diet changes or therapeutic administration to minimize 
the risk for stone development.  With human presence in microgravity a continuing presence and exploration class 
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